Literature DB >> 16311415

Treatment of pituitary tumors: somatostatin.

Maria A Tichomirowa1, Adrian F Daly, Albert Beckers.   

Abstract

Somatostatin is an important physiological regulator of neuroendocrine function across multiple biological systems, including the brain and the gastrointestinal tract. In the pituitary gland, somatostatin regulates the secretion of hormones such as growth hormone and thyroid-stimulating hormone in healthy and pathological states. The short half-life of somatostatin makes it unsuitable for clinical use in chronic diseases, which led to the development of long-acting somatostatin analogs for the treatment of acromegaly and thyroid-stimulating hormone-secreting adenomas, which were administered by intermittent injection twice or three times a day. More recently, depot versions have been developed that permit dosing once every month. This review assesses the efficacy of somatostatin analogs in the treatment of pituitary adenomas, including acromegaly, thyroid-stimulating hormone-secreting tumors, non-functioning adenomas, and Cushing's disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16311415     DOI: 10.1385/ENDO:28:1:093

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  94 in total

1.  Biologic and immunologic activities and applications of somatostatin analogs.

Authors:  W Vale; J Rivier; N Ling; M Brown
Journal:  Metabolism       Date:  1978-09       Impact factor: 8.694

Review 2.  Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly.

Authors:  John S Bevan
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

3.  The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.

Authors:  Leo J Hofland; Joost van der Hoek; Richard Feelders; Maarten O van Aken; Peter M van Koetsveld; Marlijn Waaijers; Diana Sprij-Mooij; Christian Bruns; Gisbert Weckbecker; Wouter W de Herder; Albert Beckers; Steven W J Lamberts
Journal:  Eur J Endocrinol       Date:  2005-04       Impact factor: 6.664

4.  C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest.

Authors:  K Sharma; Y C Patel; C B Srikant
Journal:  Mol Endocrinol       Date:  1999-01

Review 5.  Oncological applications of somatostatin analogues.

Authors:  A V Schally
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

6.  A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.

Authors:  Shlomo Melmed; Richard Sternberg; David Cook; Anne Klibanski; Philippe Chanson; Vivien Bonert; Mary Lee Vance; David Rhew; David Kleinberg; Ariel Barkan
Journal:  J Clin Endocrinol Metab       Date:  2005-04-12       Impact factor: 5.958

Review 7.  Distribution of somatostatin receptors in normal and tumor tissue.

Authors:  J C Reubi; L Kvols; E Krenning; S W Lamberts
Journal:  Metabolism       Date:  1990-09       Impact factor: 8.694

Review 8.  Somatostatin receptors in brain and pituitary.

Authors:  J Epelbaum; F Agid; Y Agid; A Beaudet; P Bertrand; A Enjalbert; V Heidet; C Kordon; S Krantic; J F Léonard
Journal:  Horm Res       Date:  1989

Review 9.  Lanreotide Autogel for acromegaly: a new addition to the treatment armamentarium.

Authors:  Antonio Ciccarelli; Adrian Daly; Albert Beckers
Journal:  Treat Endocrinol       Date:  2004

10.  One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.

Authors:  Ph Caron; M Bex; D R Cullen; U Feldt-Rasmussen; A M Pico Alfonso; S Pynka; K Racz; J Schopohl; A Tabarin; M J Valimaki
Journal:  Clin Endocrinol (Oxf)       Date:  2004-06       Impact factor: 3.478

View more
  4 in total

1.  Theoretical analysis of somatostatin receptor 5 with antagonists and agonists for the treatment of neuroendocrine tumors.

Authors:  Santhosh Kumar Nagarajan; Sathya Babu; Thirumurthy Madhavan
Journal:  Mol Divers       Date:  2017-02-02       Impact factor: 2.943

Review 2.  PI3K/Akt/mTOR and Raf/MEK/ERK signaling pathways perturbations in non-functioning pituitary adenomas.

Authors:  Hadara Rubinfeld; Ilan Shimon
Journal:  Endocrine       Date:  2012-05-03       Impact factor: 3.633

3.  Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization.

Authors:  Michael Grant; Haydar Alturaihi; Philippe Jaquet; Brian Collier; Ujendra Kumar
Journal:  Mol Endocrinol       Date:  2008-07-24

4.  Regulation of lifespan by chemosensory and thermosensory systems: findings in invertebrates and their implications in mammalian aging.

Authors:  Dae-Eun Jeong; Murat Artan; Keunhee Seo; Seung-Jae Lee
Journal:  Front Genet       Date:  2012-10-18       Impact factor: 4.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.